Are Predators Circling GlaxoSmithKline plc?

Is GlaxoSmithKline plc (LON:GSK) Getting Ready To Defend Itself From A Takeover?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It emerged at the beginning of this month that drugs giant Pfizer had approached GlaxoSmithKline (LSE: GSK) about a possible takeover sometime during October. According to the Financial Times, Pfizer had “looked seriously at GlaxoSmithKline as a potential target”, but the US group had received a cold reception from Glaxo’s management and the talks are now dead. 

After testing the waters at Glaxo, Pfizer moved on to smaller peer Allergan. The two pharma groups are now having “friendly discussions” about the possibility of a merger. 

However, Pfizer’s interest in Glaxo has sparked a very interesting debate. Indeed, many City analysts and key investors are now starting to wonder if another member of the Big Pharma club will make an offer for Glaxo.

If Pfizer’s interested, it’s more than likely that other companies are also interested in Glaxo as well…

Fending off offers 

Soon after Glaxo’s management rebuffed Pfizer’s approach, the company revealed the details of dozens of new drugs that it has under development, which the group says will help drive its recovery — the same path AstraZeneca took when it turned down an approach from Pfizer last year. 

Glaxo unveiled 40 experimental treatments and vaccines for conditions ranging from cancer and HIV to asthma and shingles. The new treatment showcase was an attempt to convince investors that Glaxo is heading in the right direction. According to Glaxo’s management the company has the potential to file up to 20 new drugs with regulators before 2020. Chief executive Sir Andrew Witty said the “breadth and richness” of Glaxo’s pipeline should prove to investors that the company can prosper alone.

Struggling 

Glaxo isn’t the only company in the Big Pharma group that’s struggling to return to growth. France’s Sanofi recently announced that its sales growth would slow to 3% to 4% per annum between 2015 and 2020. Moreover, Sanofi’s management expects little growth in earnings per share for the next two years, similar to Glaxo’s forecast.

Meanwhile, other European peers such as Roche and Novartis are chalking up high-single-digit growth rates, and these two pharma giants could easily boost their sales base by buying either Glaxo or Sanofi. 

In dollar terms, Glaxo is one of the smallest of the Big Pharma group with a market cap of $100bn. Roche, Pfizer, and Novartis are all twice the size of Glaxo with market values of $228bn, $208bn and $235bn respectively. The industry’s largest player Johnson & Johnson is nearly three times the size of Glaxo with a market value of $280bn. 

Is a takeover coming? 

So, is Glaxo about to be taken over by a larger peer? Well, the company certainly looks as if it’s putting up defences against any offer. Pfizer’s interest in the company certainly signals that potential buyers are prepared to make an offer for Glaxo. Although, it remains to be seen what sort of price will be offered and how long it will take for an offer to emerge. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »